JPWO2019226611A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019226611A5 JPWO2019226611A5 JP2020565431A JP2020565431A JPWO2019226611A5 JP WO2019226611 A5 JPWO2019226611 A5 JP WO2019226611A5 JP 2020565431 A JP2020565431 A JP 2020565431A JP 2020565431 A JP2020565431 A JP 2020565431A JP WO2019226611 A5 JPWO2019226611 A5 JP WO2019226611A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleosides
- pharmaceutical composition
- pharmaceutically acceptable
- nephropathy
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023040313A JP2023075283A (ja) | 2018-05-22 | 2023-03-15 | Ａｐｏｌ１発現のモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862674865P | 2018-05-22 | 2018-05-22 | |
| US62/674,865 | 2018-05-22 | ||
| PCT/US2019/033244 WO2019226611A1 (fr) | 2018-05-22 | 2019-05-21 | Modulateurs de l'expression d'apol1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023040313A Division JP2023075283A (ja) | 2018-05-22 | 2023-03-15 | Ａｐｏｌ１発現のモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525084A JP2021525084A (ja) | 2021-09-24 |
| JPWO2019226611A5 true JPWO2019226611A5 (fr) | 2022-03-24 |
| JP7247227B2 JP7247227B2 (ja) | 2023-03-28 |
Family
ID=68613945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565431A Active JP7247227B2 (ja) | 2018-05-22 | 2019-05-21 | Ａｐｏｌ１発現のモジュレーター |
| JP2023040313A Pending JP2023075283A (ja) | 2018-05-22 | 2023-03-15 | Ａｐｏｌ１発現のモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023040313A Pending JP2023075283A (ja) | 2018-05-22 | 2023-03-15 | Ａｐｏｌ１発現のモジュレーター |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10927377B2 (fr) |
| EP (1) | EP3799570A4 (fr) |
| JP (2) | JP7247227B2 (fr) |
| KR (1) | KR20210011981A (fr) |
| CN (3) | CN118127019A (fr) |
| AR (1) | AR115416A1 (fr) |
| AU (1) | AU2019274461A1 (fr) |
| BR (1) | BR112020023436A2 (fr) |
| CA (1) | CA3099750A1 (fr) |
| CL (1) | CL2020003010A1 (fr) |
| CO (1) | CO2020015377A2 (fr) |
| CR (1) | CR20200631A (fr) |
| EA (1) | EA202092748A1 (fr) |
| EC (1) | ECSP20082339A (fr) |
| IL (1) | IL278785A (fr) |
| JO (1) | JOP20200291A1 (fr) |
| MA (1) | MA53924A (fr) |
| MX (1) | MX2020012497A (fr) |
| NI (1) | NI202000085A (fr) |
| PE (1) | PE20211397A1 (fr) |
| PH (1) | PH12020551995A1 (fr) |
| SG (1) | SG11202011397QA (fr) |
| WO (1) | WO2019226611A1 (fr) |
| ZA (1) | ZA202007537B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49076E1 (en) | 2010-04-18 | 2022-05-17 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| PE20211397A1 (es) | 2018-05-22 | 2021-07-27 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de apol1 |
| US11976067B2 (en) | 2022-01-18 | 2024-05-07 | Maze Therapeutics, Inc. | APOL1 inhibitors and methods of use |
| WO2024040235A1 (fr) * | 2022-08-19 | 2024-02-22 | Maze Therapeutics, Inc. | Inhibiteurs d'apol1 et procédés d'utilisation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US9023355B2 (en) | 2010-04-13 | 2015-05-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| WO2013119979A1 (fr) | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Méthodes et compositions permettant de moduler l'expression du facteur vii |
| US10130632B2 (en) * | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| EP2972381A2 (fr) | 2013-03-14 | 2016-01-20 | Galapagos NV | Cibles et composés moléculaires, et procédés pour les identifier, utiles dans le traitement de maladies associées à une transition épithélio-mésenchymateuse |
| TWI657819B (zh) * | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| TW201718010A (zh) * | 2015-06-19 | 2017-06-01 | 健臻公司 | 治療原發性局部節段性腎小球硬化症之方法 |
| EP3353328A4 (fr) | 2015-09-24 | 2019-06-12 | Ionis Pharmaceuticals, Inc. | Modulateurs de l'expression de kras |
| PE20211397A1 (es) | 2018-05-22 | 2021-07-27 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de apol1 |
-
2019
- 2019-05-21 PE PE2020001880A patent/PE20211397A1/es unknown
- 2019-05-21 CN CN202410386618.XA patent/CN118127019A/zh active Pending
- 2019-05-21 CR CR20200631A patent/CR20200631A/es unknown
- 2019-05-21 AU AU2019274461A patent/AU2019274461A1/en active Pending
- 2019-05-21 EA EA202092748A patent/EA202092748A1/ru unknown
- 2019-05-21 JP JP2020565431A patent/JP7247227B2/ja active Active
- 2019-05-21 WO PCT/US2019/033244 patent/WO2019226611A1/fr unknown
- 2019-05-21 JO JOP/2020/0291A patent/JOP20200291A1/ar unknown
- 2019-05-21 BR BR112020023436-2A patent/BR112020023436A2/pt unknown
- 2019-05-21 CN CN201980033544.9A patent/CN112423792B/zh active Active
- 2019-05-21 MX MX2020012497A patent/MX2020012497A/es unknown
- 2019-05-21 US US16/418,060 patent/US10927377B2/en active Active
- 2019-05-21 CN CN202410386621.1A patent/CN118127020A/zh active Pending
- 2019-05-21 KR KR1020207036583A patent/KR20210011981A/ko active Search and Examination
- 2019-05-21 CA CA3099750A patent/CA3099750A1/fr active Pending
- 2019-05-21 EP EP19807789.3A patent/EP3799570A4/fr active Pending
- 2019-05-21 MA MA053924A patent/MA53924A/fr unknown
- 2019-05-21 SG SG11202011397QA patent/SG11202011397QA/en unknown
- 2019-05-22 AR ARP190101365A patent/AR115416A1/es unknown
-
2020
- 2020-09-18 US US17/025,239 patent/US11525136B2/en active Active
- 2020-11-17 IL IL278785A patent/IL278785A/en unknown
- 2020-11-18 PH PH12020551995A patent/PH12020551995A1/en unknown
- 2020-11-19 CL CL2020003010A patent/CL2020003010A1/es unknown
- 2020-11-20 NI NI202000085A patent/NI202000085A/es unknown
- 2020-12-03 ZA ZA2020/07537A patent/ZA202007537B/en unknown
- 2020-12-09 CO CONC2020/0015377A patent/CO2020015377A2/es unknown
- 2020-12-18 EC ECSENADI202082339A patent/ECSP20082339A/es unknown
-
2022
- 2022-11-08 US US18/053,447 patent/US20230265428A1/en active Pending
-
2023
- 2023-03-15 JP JP2023040313A patent/JP2023075283A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530325A5 (fr) | ||
| JP2021072840A5 (fr) | ||
| JP2020022483A5 (fr) | ||
| JP2017513469A5 (fr) | ||
| JP3479068B2 (ja) | ５−フルオロ−２’−デオキシ−３’−チアシチジンのｂ型肝炎治療への使用 | |
| Miyasaka et al. | A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio) thymine | |
| TW401402B (en) | Novel N-heterocyclyl sulfonamides and pharmaceutical composition and preparation process thereof | |
| JP2020193199A5 (fr) | ||
| JP2023058575A5 (fr) | ||
| JP2021074010A5 (fr) | ||
| JPH08508491A (ja) | ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド | |
| JPS6254315B2 (fr) | ||
| JP2005530736A5 (fr) | ||
| JP2020511943A5 (fr) | ||
| JP2004244422A (ja) | 抗−ｂ型肝炎（ｈｂｖ）及び抗−ｈｉｖ剤としてのｌ−２’，３’−ジデオキシヌクレオシド類似体 | |
| JP2007505138A5 (fr) | ||
| JP2005529155A5 (fr) | ||
| JPH01151595A (ja) | 治療に使用するための化合物 | |
| WO2009067409A1 (fr) | Nucléosides substitués en position 2',4' en tant qu'agents antiviraux | |
| JP2013538560A5 (fr) | ||
| JPH07300493A (ja) | ２′−エーテル基を有する、ヌクレオシド及びオリゴヌクレオチド | |
| WO2009009625A2 (fr) | Dérivés nucléosidiques substitués ayant des propriétés antivirales et antimicrobiennes | |
| JP2019525918A5 (fr) | ||
| JP2023011793A5 (fr) | ||
| JP2017532982A5 (fr) |